Sold as Manganese Sulfate. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Manganese Sulfate (sold as Manganese Sulfate), first approved May 5, 1987, with 0 new uses approved and 0 published complete response letters.
| Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS StudyERAS, Compliance · Aristotle University Of Thessaloniki | Not applicable | Recruiting | Oct 7, 2025 |
| Effect of Probiotics After NeurosurgeryHealing · University Maribor | Not applicable | Recruiting | Oct 1, 2025 |
| Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's DiseaseParkinson Disease, Depression · University of British Columbia | Phase 2 | Recruiting | Oct 5, 2022 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| May 5, 1987 | Manganese SulfateNDA 19228 · New formulation or manufacturer | Abraxis Pharm | 3 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Abraxis Pharm